Translationally, these mechanisms map onto actionable biomarkers,RAD51 suppression, TRPV2 activity, NF-κB/STAT3 and Wnt/β-cateninsignatures, that can guide patient selection and pharmacodynamic readoutsin early phase GBM trials. This evidence concerns the gene TRPV2 and glioblastoma.